English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Summary   Background  Guselkumab is an interleukin‐23 inhibitor indicated for the treatment of moderate‐to‐severe plaque psoriasis in adults. Guselkumab has demonstrated additional benefit in patients with early inadequate response to ustekinumab. Long‐term efficacy comparisons of guselkumab and ustekinumab are currently lacking among ustekinumab‐naive patients.    Objectives  To assess the relative efficacy of guselkumab and ustekinumab for maintenance therapy of moderate‐to‐severe plaque psoriasis, using individual patient data ( IPD ) from randomized controlled trials.    Methods   IPD  for guselkumab from the  VOYAGE  1 and 2 trials were pooled and compared with  IPD  for ustekinumab from the  NAVIGATE  trial. Multivariable logistic regression analyses compared guselkumab 100 mg and ustekinumab 45 mg or 90 mg for the achievement and maintenance of Psoriasis Area and Severity Index ( PASI ) 90, 75 and 100 responses up to 40 weeks. The regression models accounted for a range of clinically relevant covariates (e.g. age, sex, psoriasis duration). Relative efficacy was expressed using odds ratios ( OR s) and predicted probability of treatment response associated with each intervention.    Results  Patients receiving guselkumab had significantly higher probabilities of achieving a  PASI  90 response than patients receiving ustekinumab, at both week 16 [70·4% vs. 46·0%,  OR  2·79, 95% confidence interval ( CI ) 2·22–3·45] and week 40 (74·2% vs. 54·5%,  OR  2·40, 95%  CI  1·89–3·13]. Guselkumab was also associated with a significantly increased likelihood of achieving both  PASI  75 and  PASI  100 responses at weeks 16 and 40, compared with ustekinumab.    Conclusions  Adjusted analyses leveraging  IPD  demonstrate that guselkumab has a significantly higher probability of achieving and maintaining  PASI  treatment responses through week 40 than ustekinumab does.   Linked Comment:   Yiu. Br J Dermatol 2020; 183:202–203.

Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate‐to‐severe plaque psoriasis: the COMPASS analysis